Synergistic interactions between DMAG and mitogen- activated protein kinase kinase 1/2 inhibitors in Bcr/abl+ leukemia cells sensitive and resistant to imatinib mesylate
Research output: Contribution to journal › Article › peer-review
21Scopus
citations
Fingerprint
Dive into the research topics of 'Synergistic interactions between DMAG and mitogen- activated protein kinase kinase 1/2 inhibitors in Bcr/abl+ leukemia cells sensitive and resistant to imatinib mesylate'. Together they form a unique fingerprint.